NEW YORK (GenomeWeb) – Curiox Biosystems this week announced two collaborations with Singapore's Agency for Science, Technology, and Research (A*Star) to validate the company's DropArray system for immunomonitoring.
The first collaboration is with the Singapore Immunology Network (SIgN), an A*Star research institute, which has implemented the DropArray system on its immunomonitoring platform to validate the use of the technology with Luminex assays. SIgN researchers successfully tested the system and executed their clinical assays on it, Curiox said, adding that they have achieved 65 percent savings in overall assay costs, along with reduced use of clinical samples.
The SigN researchers now plan to use DropArray to minimize sample and reagent use from Luminex bead-based multiplexing kits.
Another collaboration is with A*Star's Institute of Molecular and Cellular Biology. Frederic Bard, senior principal investigator there, has established a genome-wide RNAi screening program focused on membrane trafficking regulation, Golgi organization, and Golgi signaling to control protein glycosylation. Bard and his team are now optimizing DropArray for RNA transfection with suspension cells, Curiox said.
Curiox is a bioinstrumentation firm spun out of A*Star in 2008. The DropArray technology consists of microplates comprising a hydrophobic planar surface with 96- or 384-hydrophobic features arrayed in SBS/ANSI format, according to the company's website.